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There are 28 approved antiretroviral drugs for the treat-
ment of HIV infection; combinations of these drugs
clearly change the natural history of HIV, dramatically
decreasing HIV-related morbidity and mortality and
promoting and prolonging healthy survival. Despite the
benefits of HIV treatment, some antiretroviral regimens
may be inconvenient, toxic, and/or have suboptimal
antiretroviral activity, particularly against drug-resistant
viral strains. Thus, newer compounds are needed that
continue to improve convenience and tolerability,
reduce toxicity, and improve antiretroviral activity, parti-
cularly against drug-resistant viruses. Additionally,
newer drugs may better penetrate tissue reservoirs (e.g.
genital tract, central nervous system) and/or exploit new
viral or cellular targets with new mechanisms of action.
In addition to the direct antiretroviral action, some
investigational agents may target inflammation and/or
immune responses. Finally, newer formulations of anti-
retroviral agents may allow additional options for one-
pill, once-daily dosing or allow less frequent dosing than
once-daily, perhaps as infrequently as once-monthly or
once-quarterly parenteral dosing.
There are a number of investigational antiretroviral
agents currently in development. These include newer
antiretroviral agents in existing classes, including new
nucleoside reverse transcriptase inhibitors, non-nucleoside
reverse transcriptase inhibitors, integrase inhibitors, and
entry inhibitors. Of those in the pipeline, a few com-
pounds are in advanced stages of development: Tenofovir
alafenamide fumarate (TAF) is a nucleoside analogue
reverse transcriptase inhibitor currently in phase 3 that is
potent and potentially less toxic than the current TDF
formulation. Doravirine (formerly MK-1439) is a non-
nucleoside analogue reverse transcriptase inhibitor cur-
rently in phase 2 that demonstrates activity against
NNRTI-resistant viral strains. GSK ‘744 is an integrase
inhibitor currently in phase 2, being developed in a long-
acting preparation. In addition there are investigational
drugs with new mechanisms of action in development:
BMS-663,068, is a small molecule CD4 attachment inhibi-
tor that completed phase 1 testing. Cenicriviroc is a novel
CCR5/CCR2 antagonist currently in phase 3 that offers
both antiretroviral activity and the potential for an anti-
inflammatory effect (through CCR2 antagonism). A num-
ber of other compounds are in earlier stages of pre-clinical
and clinical development.
The clinical use of these newer agents and formulations
will depend on the results of clinical trials, and the time-
line for development and availability. Continued progress
in HIV drug development will allow improvements in the
clinical care of patients living with HIV infection.
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